<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57106">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362646</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-1078-0008</org_study_id>
    <secondary_id>2U01HL088942-07</secondary_id>
    <nct_id>NCT02362646</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients</brief_title>
  <official_title>Safety &amp; Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annetine Gelijns</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this research is to determine whether injecting mesenchymal precursor
      cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD)
      is safe. MPCs are normally present in human bone marrow and have been shown to increase the
      development of blood vessels and new heart muscle cells in the heart. In addition, this
      research is being done to test whether injecting the MPCs into the heart is effective in
      improving heart function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intramyocardial injection of mesenchymal precursor cells (MPC) in patients with advanced
      heart failure who are treated with left ventricular assist device (LVAD) implantation may
      result in a renewable source of proliferating functional cardiomyocytes; induce development
      of capillaries and larger-size blood vessels to supply oxygen and nutrients to endogenous
      myocardium and newly-implanted cardiomyocytes; and release factors capable of paracrine
      signaling.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Status</measure>
    <time_frame>up to 6 months</time_frame>
    <description>functional status, defined by the number of temporary weans from LVAD support tolerated over the 6 months post-randomization. A successful wean is the ability to tolerate temporary weaning from LVAD support for 30 minutes without sustained symptoms of worsening heart failure. Wean failures are defined as inability to tolerate the temporary wean for 30 minutes; death; or patient too unstable, in the judgment of the primary heart failure cardiologist, to tolerate the wean attempt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Safety: Incidence of the study intervention-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiologic Assessments</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Echocardiographic assessments of the myocardial size and function by transthoracic echocardiography with LVAD at full support, and as tolerated following 6-Minute Walk Test (MWT) while weaned from LVAD support (for patients who tolerate wean from LVAD support for 30 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological assessments of myocardial tissue</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QoL)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Quality of life will be assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ), a widely used tool in heart failure populations, and the Short Form 12 (SF12), a widely used overall health status measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopkins Verbal Learning Test</measure>
    <time_frame>3 months and 12 months</time_frame>
    <description>Cognitive performance will be assessed Hopkins Verbal Learning Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trailmaking Tests A and B</measure>
    <time_frame>3 months and 12 months</time_frame>
    <description>Cognitive performance will be assessed using Trailmaking Tests A and B. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCG Complex Figures</measure>
    <time_frame>3 months and 12 months</time_frame>
    <description>Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Span</measure>
    <time_frame>3 months and 12 months</time_frame>
    <description>Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Symbol Substitution Test</measure>
    <time_frame>3 months and 12 months</time_frame>
    <description>Cognitive performance will be assessed using the Digit Symbol Substitution Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Controlled Oral Word Association</measure>
    <time_frame>3 months and 12 months</time_frame>
    <description>Cognitive performance will be assessed using the Controlled Oral Word Association. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Length of stay of index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Frequency and cause of readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Costs</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Hospital resource use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status</measure>
    <time_frame>up to 12 months</time_frame>
    <description>functional status, defined by the number of temporary weans from LVAD support tolerated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathy</condition>
  <condition>Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>MPC Intramyocardial Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramyocardial injections of 150 million MPCs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Solution</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MPC Intramyocardial Injection</intervention_name>
    <description>Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation</description>
    <arm_group_label>MPC Intramyocardial Injection</arm_group_label>
    <other_name>Mesenchymal Precursor Cell Injection</other_name>
    <other_name>RevascorTM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Solution</intervention_name>
    <arm_group_label>Control Solution</arm_group_label>
    <other_name>50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO</other_name>
    <other_name>Cryoprotective media</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent, inclusive of release of medical information, and Health
             Insurance Portability and Accountability Act (HIPAA) documentation

               -  Age 18 years or older

               -  If the subject or partner is of childbearing potential, he or she must be
                  willing to use adequate contraception (hormonal or barrier method or abstinence)
                  from the time of screening and for a period of at least 16 weeks after procedure

               -  Female subjects of childbearing potential must have a negative serum pregnancy
                  test at screening

               -  Admitted to the clinical center at the time of randomization

               -  Clinical indication and accepted candidate for implantation of an FDA-approved
                  (US sites only) or Health Canada-approved (Canadian sites only) implantable,
                  non-pulsatile LVAD as a bridge to transplantation or for destination therapy.

        Exclusion Criteria:

          -  Planned percutaneous LVAD implantation

               -  Anticipated requirement for biventricular mechanical support

               -  Concomitant arrhythmia ablation at time of LVAD implantation

                  -- Planned aortic valve intervention for aortic insufficiency at the time of
                  LVAD implantation

               -  Cardiothoracic surgery within 30 days prior to randomization

               -  Spontaneous myocardial infarction related to ischemia due to a primary coronary
                  event such as unstable plaque rupture, erosion or dissection within 30 days
                  prior to randomization

               -  Prior cardiac transplantation, LV reduction surgery, or cardiomyoplasty

               -  Acute reversible cause of heart failure (e.g. myocarditis, profound
                  hypothyroidism)

               -  Stroke within 30 days prior to randomization

               -  Platelet count &lt; 100,000/ul within 24 hours prior to randomization

               -  Acute infectious process: acute bacterial, fungal, or viral disease OR acute
                  exacerbation of chronic infectious disease such as hepatitis

               -  Presence of &gt;10% anti-HLA antibody titers with known specificity to MPC donor
                  HLA antigens

               -  A known hypersensitivity to dimethyl sulfoxide (DMSO), murine, and/or bovine
                  products

               -  History of a known active malignancy within the past 3 years except for
                  localized prostate cancer, cervical carcinoma in situ, breast cancer in situ, or
                  nonmelanoma skin cancer that has been definitively treated

               -  Presence of human immunodeficiency virus (HIV)

               -  Received investigational intervention within 30 days prior to randomization

               -  Treatment and/or an incomplete follow-up treatment of any investigational cell
                  based therapy within 6 months prior to randomization

               -  Active participation in other research therapy for cardiovascular
                  repair/regeneration

               -  Prior recipient of stem precursor cell therapy for cardiac repair

               -  Pregnant or breastfeeding at time of randomization.

               -  History of known or suspected hypercoagulable state in the opinion of the
                  investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick O'Gara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Weisel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annetine Gelijns, PhD</last_name>
    <phone>212-659-9567</phone>
    <email>annetine.gelijns@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Moquete, BSN</last_name>
    <phone>212-659-9651</phone>
    <email>ellen.moquete@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bowdish, MD</last_name>
      <phone>323-442-5849</phone>
      <email>michael.bowdish@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Edward Lozano</last_name>
      <phone>323-409-5573</phone>
      <email>edwardlo@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Bowdish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Woo, MD</last_name>
      <phone>650-725-3828</phone>
      <email>joswoo@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kokil Bakshi</last_name>
      <phone>650-498-1232</phone>
      <email>kbakshi@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartley Griffith, MD</last_name>
      <phone>410-328-3822</phone>
      <email>bgriffith@smail.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zahid Noor, PhD</last_name>
      <phone>410-328-4914</phone>
      <email>zanoor@som.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bartley Griffith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Pagani, MD, PhD</last_name>
      <phone>734-647-2894</phone>
      <email>fpagani@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lydia McGowan, MS, CCRP</last_name>
      <phone>734-647-7958</phone>
      <email>lydiamcg@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Francis Pagani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Nemeh, MD</last_name>
      <email>HNEMEH1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Carly Cavazos</last_name>
      <phone>(313) 916-5619</phone>
      <email>ccavazo1@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Hassan Nemeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Heart Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Goldstein, MD</last_name>
      <phone>718-920-2144</phone>
      <email>dgoldste@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Juan Garcia, RN</last_name>
      <phone>718-920-6742</phone>
      <email>jugarcia@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshifumi Naka, MD</last_name>
      <phone>212-305-0828</phone>
      <email>yn33@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lyn Goldsmith, MA, RN, CCRC</last_name>
      <phone>212-342-0261</phone>
      <email>lg2240@columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Yoshifuma Naka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Milano, MD</last_name>
      <phone>919-684-3243</phone>
      <email>carmelo.milano@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Lane, BSN, RN, CRCIII</last_name>
      <phone>(919) 684-2037</phone>
      <email>kathleen.lane@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carmelo Milano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nader Moazami, MD</last_name>
      <phone>216-444-6708</phone>
      <email>moazamn@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Garcia, B.S.N., CCRC</last_name>
      <phone>(216) 444-7753</phone>
      <email>GARCIAM1@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nader Moazami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Fadorson</last_name>
      <email>Denise.Fadorsen@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Bryan Whitson, Whitson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavan Atluri, MD</last_name>
      <phone>215-662-2956</phone>
      <email>pavan.atluri@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Lou Mayer, BSN, CCRN, CCRC</last_name>
      <phone>215-662-7981</phone>
      <email>Marylou.mayer@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pavan A Atluri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kormos, MD</last_name>
      <phone>412-648-6259</phone>
      <email>kormosrl@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Liz Younkin, RN</last_name>
      <phone>412-647-0749</phone>
      <email>younkineaq@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Kormos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Lima, MD</last_name>
      <phone>214-820-7100</phone>
      <email>Brian.lima@baylorhealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jasmin Cochran</last_name>
      <email>Jasmine.Cochran@BSWHealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Lima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Selzman, MD</last_name>
      <phone>801-587-9348</phone>
      <email>Craig.Selzman@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Camila Varga</last_name>
      <phone>801-587-9185</phone>
      <email>Camila.vargas@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Craig Selzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Kern, MD</last_name>
      <phone>434-982-4301</phone>
      <email>jak3r@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Burks, RN</last_name>
      <phone>434-243-0315</phone>
      <email>sgb2c@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Kern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53726</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takushi Kohmoto, MD</last_name>
      <phone>608-262-0540</phone>
    </contact>
    <contact_backup>
      <last_name>Adam Krajewski</last_name>
      <phone>(608) 262-9383</phone>
      <email>krajewski@surgery.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Takushi Kohmoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John C Mullen, MD, MSc</last_name>
      <phone>650-725-3828</phone>
      <email>jmullen@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Asvina Bissounauth</last_name>
      <phone>780-407-6327</phone>
      <email>asvina.bissonauth@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>John C Mullen, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrance Yau, MD, MSc</last_name>
      <phone>416-340-4074</phone>
      <email>terry.yau@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Katherine Tsang, RN, BScN</last_name>
      <phone>416-340-3280</phone>
      <email>Katherine.Tsang@uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Terrence Yau, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie de Quebec (Hopital Laval)</name>
      <address>
        <city>Qu√©bec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Charbonneau, MD</last_name>
      <phone>418-656-4717</phone>
      <email>eric.charbonneau@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Landry</last_name>
      <phone>418 656-8711</phone>
      <phone_ext>5751</phone_ext>
      <email>Patricia.Landry@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Charbonneau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ctsurgerynet.org/</url>
    <description>Cardiothoracic Surgical Network Website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>February 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Annetine Gelijns</investigator_full_name>
    <investigator_title>Chair, Department of Population Health Science &amp; Policy; Edmond A. Guggenheim Professor of Health Policy; Co-Director, InCHOIR</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Left Ventricular Assist Device</keyword>
  <keyword>Heart Transplantation</keyword>
  <keyword>Cardiomyopathy, Destination Therapy</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Bridge to Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
